JP2018109022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018109022A5 JP2018109022A5 JP2018022248A JP2018022248A JP2018109022A5 JP 2018109022 A5 JP2018109022 A5 JP 2018109022A5 JP 2018022248 A JP2018022248 A JP 2018022248A JP 2018022248 A JP2018022248 A JP 2018022248A JP 2018109022 A5 JP2018109022 A5 JP 2018109022A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- inhibitor
- medicament
- mutation
- raf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 230000002062 proliferating Effects 0.000 claims 8
- 101700004551 BRAF Proteins 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 229940121647 EGFR inhibitors Drugs 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 108010022830 Cetuximab Proteins 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 229960001433 Erlotinib Drugs 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940000425 combination drugs Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019174353A JP6974669B2 (ja) | 2012-08-07 | 2019-09-25 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680473P | 2012-08-07 | 2012-08-07 | |
| US61/680,473 | 2012-08-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526606A Division JP6342396B2 (ja) | 2012-08-07 | 2013-08-05 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019174353A Division JP6974669B2 (ja) | 2012-08-07 | 2019-09-25 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018109022A JP2018109022A (ja) | 2018-07-12 |
| JP2018109022A5 true JP2018109022A5 (US20070167479A1-20070719-C00034.png) | 2018-10-25 |
| JP6595024B2 JP6595024B2 (ja) | 2019-10-23 |
Family
ID=48980368
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526606A Active JP6342396B2 (ja) | 2012-08-07 | 2013-08-05 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
| JP2018022248A Active JP6595024B2 (ja) | 2012-08-07 | 2018-02-09 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
| JP2019174353A Active JP6974669B2 (ja) | 2012-08-07 | 2019-09-25 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526606A Active JP6342396B2 (ja) | 2012-08-07 | 2013-08-05 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019174353A Active JP6974669B2 (ja) | 2012-08-07 | 2019-09-25 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
Country Status (39)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102112885B1 (ko) * | 2012-08-07 | 2020-05-19 | 노파르티스 아게 | B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물 |
| PT2976106T (pt) | 2013-03-21 | 2021-05-26 | Array Biopharma Inc | Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor |
| WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| CN106574297B (zh) * | 2014-06-16 | 2020-07-21 | 环球创新网络公司 | 选择用于癌症治疗的个体化三联疗法的方法 |
| WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
| JP2018525402A (ja) * | 2015-08-28 | 2018-09-06 | ノバルティス アーゲー | Ｐｉ３ｋ阻害剤のアルペリシブおよびｂ−ｒａｆ阻害剤のダブラフェニブを含む組合せ医薬、がんの治療または予防におけるそのような組合せの使用 |
| EP3380097A2 (en) * | 2015-08-28 | 2018-10-03 | Novartis AG | Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| JP6805336B2 (ja) * | 2016-06-03 | 2020-12-23 | アレイ バイオファーマ、インコーポレイテッド | 薬学的組み合わせ |
| US10973829B2 (en) | 2016-09-19 | 2021-04-13 | Novartis Ag | Therapeutic uses of a C-RAF inhibitor |
| US11266653B2 (en) | 2017-05-02 | 2022-03-08 | Novartis Ag | Combination therapy |
| JP2020529411A (ja) * | 2017-08-03 | 2020-10-08 | ノバルティス アーゲー | 第三世代ｅｇｆｒチロシンキナーゼ阻害剤とｒａｆ阻害剤の治療用組合せ |
| SI3860998T1 (sl) | 2018-10-05 | 2024-06-28 | Annapurna Bio Inc. | Spojine in sestavki za zdravljenje stanj, povezanih z aktivnostjo apj-receptorja |
| EP3914591A4 (en) * | 2019-01-25 | 2022-11-09 | BeiGene, Ltd. | STABLE SOLID B-RAF KINASE DIMER INHIBITOR DISPERSIONS, METHODS OF PREPARING THEM AND USES THEREOF |
| WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| WO2023145530A1 (ja) * | 2022-01-27 | 2023-08-03 | 国立大学法人東北大学 | 癌治療剤 |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024073364A1 (en) * | 2022-09-26 | 2024-04-04 | Beigene, Ltd. | Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| EP2139484B9 (en) | 2007-04-10 | 2014-06-11 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| EP2470898A4 (en) * | 2009-08-24 | 2013-03-13 | Genentech Inc | DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT IN DETECTION OF K-RAS MUTATIONS AND MEASURING RTK EXPRESSION LEVELS |
| AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| CN102665720A (zh) * | 2009-10-12 | 2012-09-12 | 葛兰素史密斯克莱有限责任公司 | 组合 |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| TR201802943T4 (tr) * | 2010-11-08 | 2018-03-21 | Novartis Ag | (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı. |
| EP2776413A1 (en) | 2011-11-10 | 2014-09-17 | Memorial Sloan-Kettering Cancer Center | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES |
| WO2013070996A1 (en) * | 2011-11-11 | 2013-05-16 | Novartis Ag | Method of treating a proliferative disease |
| KR102112885B1 (ko) * | 2012-08-07 | 2020-05-19 | 노파르티스 아게 | B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물 |
-
2013
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active IP Right Grant
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/en active Pending
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en active Application Filing
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 PH PH12015500246A patent/PH12015500246A1/en unknown
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
- 2015-06-18 HK HK15105815.5A patent/HK1204976A1/xx unknown
- 2015-11-03 HK HK15110834.2A patent/HK1211831A1/xx unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-03-19 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
